- United Kingdom
- /
- Medical Equipment
- /
- AIM:ABDX
Abingdon Health Full Year 2024 Earnings: UK£0.004 loss per share (vs UK£0.011 loss in FY 2023)
Abingdon Health (LON:ABDX) Full Year 2024 Results
Key Financial Results
- Revenue: UK£6.14m (up 52% from FY 2023).
- Net loss: UK£1.27m (loss narrowed by 63% from FY 2023).
- UK£0.004 loss per share (improved from UK£0.011 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Abingdon Health shares are down 2.7% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Abingdon Health, and understanding these should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:ABDX
Abingdon Health
Engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally.
Excellent balance sheet very low.